Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ILK | Q13418 | 1/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2055237 | 0.83 | APP (0.71) | APPCYP1A2CYP3A4CYP2C19ILK | |
| SCHEMBL793099 | 0.82 | APP (0.61) | APPCYP1A2CYP3A4CYP2C19ILK | |
| SCHEMBL229456 | 0.81 | APP (0.68) | APPCYP1A2CYP3A4CYP2C19ILK | |
| SCHEMBL28801433 | 0.79 | APP (0.64) | APPCYP1A2CYP3A4CYP2C19ILK | |
| SCHEMBL17553302 | 0.78 | APP (0.60) | APPCYP1A2CYP3A4CYP2C19ILK | |
| Hydrochloric Acid SCHEMBL17541564 | 0.77 | APP (0.59) | APPCYP1A2CYP3A4CYP2C19ILK | |
| SCHEMBL6982071 | 0.77 | APP (0.66) | APPCYP1A2CYP3A4CYP2C19ILK | |
| SCHEMBL408832 | 0.76 | NPC1 (0.59) | APPILKGAAMAPT | |
| SCHEMBL28798406 | 0.76 | APP (0.61) | APPCYP1A2CYP3A4CYP2C19ILK | |
| SCHEMBL1982972 | 0.75 | APP (0.67) | APPCYP1A2CYP3A4CYP2C19ILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | DTYMK, ITK, DCK | APP 4658/4885CYP1A2 1806/4885CYP3A4 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.